Agilent/Dako

c-erbB-2, c-neu

#A0485 · western blot

100
Citing papers
12.4k
Combined citations
Supplier page Find this product

Research areas

HER2/EGFR in Cancer Research45Breast Cancer Treatment Studies40Monoclonal and Polyclonal Antibodies Research20Breast Lesions and Carcinomas14Estrogen and related hormone effects11Cell Adhesion Molecules Research8Advanced Biosensing Techniques and Applications8Cancer Cells and Metastasis7

Papers citing this product

1
The CD44+/CD24-phenotype is enriched in basal-like breast tumors
Breast Cancer Research·2008·553 cit.·DOI
2
Specificity of HercepTest in Determining <i>HER-2</i>/<i>neu</i> Status of Breast Cancers Using the United States Food and Drug Administration–Approved Scoring System
Journal of Clinical Oncology·1999·459 cit.·DOI
3
Current issues in ER and HER2 testing by IHC in breast cancer
Modern Pathology·2008·379 cit.·DOI
4
Oestrogen receptor negative breast cancers exhibit high cytokine content
Breast Cancer Research·2007·354 cit.·DOI
5
HER-2/<i>neu</i> Analysis in Archival Tissue Samples of Human Breast Cancer: Comparison of Immunohistochemistry and Fluorescence In Situ Hybridization
Journal of Clinical Oncology·2001·326 cit.·DOI
6
HER2 testing in gastric cancer: An update
World Journal of Gastroenterology·2016·311 cit.·DOI
7
Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers
Journal of Clinical Oncology·2008·299 cit.·DOI
8
Current Perspectives on HER2 Testing: A Review of National Testing Guidelines
Modern Pathology·2003·269 cit.·DOI
9
Clinical Relevance of <i>HER2</i> Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer
Journal of Clinical Oncology·2009·257 cit.·DOI
10
Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome
Journal of Clinical Oncology·2011·256 cit.·DOI
c-erbB-2, c-neu — Evidence — PubIndex